Synthon | Spain
Synthon addresses one of the most persistent challenges in global healthcare: the accessibility of sophisticated cancer therapies. For over 30 years, they have specialized in developing complex oncology generics, successfully navigating the high technical barriers that prevent widespread production of advanced cancer drugs. By mastering the science behind these sophisticated molecules and leveraging a fully integrated manufacturing network, Synthon delivers therapies with the efficacy and safety profiles of originator products at sustainable costs. Our partnership with Synthon directly aligns with our mission to ensure that Pakistani cancer patients have access to world-class care, proving that therapeutic excellence and economic accessibility can be achieved in tandem.
Pharmacare Premium | Malta
Pharmacare Premium operates within a highly specialized domain of pharmaceutical manufacturing: the production of high-potency oncology compounds.8 Their purpose-built, EU-GMP certified facility in Malta is engineered to handle the industry’s most technically demanding therapeutics, including cytotoxic agents and immuno-oncology compounds. Their proven expertise in ‘Day 1’ generic launches provides a strategic capability, ensuring expedited access to critical post-patent therapies. This alliance secures for Pakistan a vital link to Europe’s most advanced and specialized cancer drug manufacturing infrastructure, making complex treatments safely and reliably available.
Deva Holdings | Turkey
Deva Holdings has achieved the gold standard of international pharmaceutical manufacturing, earning both EU-GMP and US-FDA certifications for its facilities.4 This dual validation by the world’s most stringent regulatory bodies provides an incontrovertible assurance of quality and consistency. With a comprehensive portfolio of over 600 products distributed in more than 50 countries, Deva combines industrial scale with unwavering adherence to global compliance standards.5 For the Pakistani market, this alliance is pivotal. It guarantees that every oncology product prescribed is backed by absolute product integrity, providing clinicians with profound confidence and patients with invaluable peace of mind.
DONGKOOK Pharmaceutical Co. Ltd. | South Korea
DONGKOOK Pharmaceutical embodies a philosophy of relentless improvement in cancer therapeutics. Their substantial and sustained investment in research and development since 1968 is a testament to their commitment to enhancing patient outcomes. A landmark achievement—the development of Asia’s first prefilled syringe system—exemplifies their focus on holistic treatment efficacy. This innovation addresses critical aspects of oncology care beyond the molecule itself: it enhances administration safety, mitigates contamination risks, and improves the patient experience. Our collaboration with DONGKOOK leverages this patient-centric innovation, ensuring that the therapies we provide are optimized for both clinical effectiveness and practical application.
Dexa Medica | Indonesia
Dexa Medica’s ascent from a nascent enterprise in 1969 to Indonesia’s preeminent pharmaceutical company is a powerful testament to sustained quality and earned trust. Achieving and maintaining market leadership in Southeast Asia’s largest and most competitive market provides objective validation of their excellence. This reputation was not acquired but built over decades of consistent performance and professional integrity. For Pakistan, Dexa Medica’s success serves as a compelling proxy for the value and reliability their oncology products command. Our partnership imports this proven excellence—a guarantee of quality validated by decades of market leadership.
https://www.dexagroup.com
CSPC Ouyi Pharmaceutical Group Ltd | China
As a constituent of the Hang Seng Index, CSPC Ouyi Pharmaceutical exemplifies the synthesis of financial strength, manufacturing scale, and scientific rigor.7 Their strategic sophistication is highlighted by a trans-Pacific research and development infrastructure spanning China and the United States. This model allows them to develop oncology therapies that meet global regulatory standards while addressing specific regional patient needs. The partnership equips Pakistani oncologists with a comprehensive, multi-tiered cancer treatment portfolio—from innovative targeted agents to essential chemotherapies—all supported by world-class R&D and formidable production capabilities.
Beijing SL Pharmaceutical Co. Ltd | China
Beijing SL Pharmaceutical operates at the frontier of oncological innovation, engineering a paradigm shift from conventional treatments to next-generation biologics. As a national high-tech enterprise, validated by prestigious scientific grants, SL PHARMA is a leader in China’s biotechnology revolution.2 Their state-of-the-art, GMP-certified facilities are dedicated to advancing gene-engineering platforms that produce sophisticated molecular medicines.3 This partnership is our conduit to the future of cancer care, enabling us to channel emerging, high-precision biotherapeutics into Pakistan’s healthcare ecosystem and equip physicians with the transformative tools of modern oncology.